{"publication_id":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","content_hash":"sha256:40dfc9e68b0bcdeb1513c586a5d6f1b21b6dbad1495ee9da74a807610f9ced84","nodes":[{"id":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","type":"publication","title":"Adjacent Evidence Brief: Sulforaphane NRF2 — full paper"},{"id":"claim_1","type":"claim","text":"This synthesis tests the thesis that evidence for Sulforaphane NRF2 is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation."},{"id":"claim_2","type":"claim","text":"Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims."},{"id":"claim_3","type":"claim","text":"This paper synthesizes evidence on Sulforaphane NRF2 across 21 included source papers and 902 high-confidence extracted claims."},{"id":"claim_4","type":"claim","text":"The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 16 adjacent clinical sources, and 5 mechanistic or model-system sources, with 5 cross-study disagreements across the evidence base."},{"id":"claim_5","type":"claim","text":"Positive study-level signals are not the dominant direction in any outcome class; null signals are not the dominant direction in any outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the contextual adjacent evidence, immune and inflammation, mechanism, and cardiometabolic outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect."},{"id":"claim_6","type":"claim","text":"The conclusion is that Sulforaphane NRF2 should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim."},{"id":"claim_7","type":"claim","text":"This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-sulforaphane_nrf2-v06-DAILY-2026-06-27T12-02-36Z`."},{"id":"claim_8","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text."},{"id":"claim_9","type":"claim","text":"Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification."},{"id":"claim_10","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, mechanism); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_11","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_12","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_13","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_14","type":"claim","text":"| Sulforaphane NRF2 / Contextual Adjacent Evidence | n=12; claims=441 | significant source statistic in 8/12 sources; receipt-level direction coded unclear | 11 indirect; 1 review | limited corpus depth in this outcome class |"},{"id":"claim_15","type":"claim","text":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate."},{"id":"claim_16","type":"claim","text":"In animal/preclinical evidence, contextual Adjacent Evidence remains a separate Results slice for Sulforaphane NRF2 (n=12; claims=441; significant source statistic in 8/12 sources; receipt-level direction coded unclear; 11 indirect; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:"},{"id":"claim_17","type":"claim","text":"Direction reconciliation: receipt-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction."},{"id":"claim_18","type":"claim","text":"Chen 2025 (Effects of azithromycin on lung oxidative injury and immune function in mice infected with Mycoplasma pneumoniae based; representative statistic p < 0.05; source-level statistic reported; direction=null; directness=mechanistic; tier=C1)."},{"id":"claim_19","type":"claim","text":"Ruhee 2025 (Effects of Sulforaphane Treatment on Skeletal Muscle from Exhaustive Exercise-Induced Inflammation and Oxidative Stress; 8 extracted claim(s); receipt-level direction is the coded finding; direction=null; directness=indirect; tier=B2)."},{"id":"claim_20","type":"claim","text":"In animal/preclinical evidence, cardiometabolic remains a separate Results slice for Sulforaphane NRF2 (n=2; claims=198; unclear signal in 1/2 sources; 2 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:"},{"id":"claim_21","type":"claim","text":"Xin 2018 (Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn; 43 extracted claim(s); receipt-level direction is the coded finding; direction=null; directness=indirect; tier=B2)."},{"id":"claim_22","type":"claim","text":"The principal limitation is evidence-role imbalance. The retained corpus contains no sources classified primarily as direct clinical evidence, 16 adjacent clinical sources, and 5 mechanistic or model-system sources, which means causal interpretation depends on how much weight is assigned to each evidence tier."},{"id":"claim_23","type":"claim","text":"A second limitation is endpoint heterogeneity. Study-level signals span the contextual adjacent evidence outcome class, the contextual adjacent evidence, immune and inflammation, cardiometabolic outcome classes, no dominant outcome class, and the contextual adjacent evidence outcome class; these domains cannot be pooled narratively without losing clinically relevant differences in measurement, population, and study design."},{"id":"claim_24","type":"claim","text":"For Sulforaphane NRF2, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging."},{"id":"claim_25","type":"claim","text":"This synthesis maps 21 included sources on Sulforaphane Nrf2 across 4 outcome classes and 5 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit."},{"id":"claim_26","type":"claim","text":"Across 21 curated reference papers, the evidence base for Sulforaphane Nrf2 shows a context-dependent profile. Positive signals appear in: contextual other. Null findings dominate: contextual other, immune inflammation. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Sulforaphane Nrf2 anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."},{"id":"claim_27","type":"claim","text":"In animal/preclinical evidence, the strongest unresolved contrast is the null vs positive between Lu 2024 and Xie 2025 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over."},{"id":"claim_28","type":"claim","text":"This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary."},{"id":"claim_29","type":"claim","text":"| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |"},{"id":"claim_30","type":"claim","text":"| cardiometabolic | 0 | 2 | null, unclear | direct interventional hard-endpoint gap |"},{"id":"source_1","type":"source","study":"The skeletal muscle slow myosin heavy chain regulates mammalian metabolic homeostasis through the NRF2 pathway","year":2026,"doi":"10.1126/sciadv.aed2478","url":"https://doi.org/10.1126/sciadv.aed2478","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Sulforaphane prevents age‐associated cardiac and muscular dysfunction through Nrf2 signaling","year":2020,"doi":"10.1111/acel.13261","url":"https://doi.org/10.1111/acel.13261","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Targeted activation of Nrf2 via sulforaphane-loaded exosomes attenuated azoospermic condition in the rat model","year":2026,"doi":"10.1038/s41598-026-40709-x","url":"https://doi.org/10.1038/s41598-026-40709-x","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"The Protective Effect of Sulforaphane on Dextran Sulfate Sodium-Induced Colitis Depends on Gut Microbial and Nrf2-Related Mechanism","year":2022,"doi":"10.3389/fnut.2022.893344","url":"https://doi.org/10.3389/fnut.2022.893344","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"The effect of dietary phytochemicals on nuclear factor erythroid 2-related factor 2 (Nrf2) activation: a systematic review of human intervention trials","year":2021,"doi":"10.1007/s11033-020-06041-x","url":"https://doi.org/10.1007/s11033-020-06041-x","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_6","type":"source","study":"Sulforaphane attenuates phosgene-induced acute lung injury via the Nrf2-HO-1/NQO1 pathway","year":2024,"doi":"10.21037/jtd-24-819","url":"https://doi.org/10.21037/jtd-24-819","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_7","type":"source","study":"Stretch Causes Cell Stress and the Downregulation of Nrf2 in Primary Amnion Cells","year":2022,"doi":"10.3390/biom12060766","url":"https://doi.org/10.3390/biom12060766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_8","type":"source","study":"Sulforaphane Alleviates Zearalenone-Induced Oxidative Stress in Bovine Mammary Epithelial Cells","year":2026,"doi":"10.3390/ani16111602","url":"https://doi.org/10.3390/ani16111602","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_9","type":"source","study":"Oxidative Stress in Keratoconus Is Evident in Tear Fluid and Stromal Cells and Alleviated in Cell Culture by Sulforaphane","year":2026,"doi":"10.1167/iovs.67.5.1","url":"https://doi.org/10.1167/iovs.67.5.1","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_10","type":"source","study":"Effects of azithromycin on lung oxidative injury and immune function in mice infected with Mycoplasma pneumoniae based on the Nrf2/ARE signaling pathway","year":2025,"doi":"10.5114/ceji.2025.152018","url":"https://doi.org/10.5114/ceji.2025.152018","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_11","type":"source","study":"Age-Related Mitochondrial Impairment and Renal Injury Is Ameliorated by Sulforaphane via Activation of Transcription Factor NRF2","year":2022,"doi":"10.3390/antiox11010156","url":"https://doi.org/10.3390/antiox11010156","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_12","type":"source","study":"Effects of Sulforaphane Treatment on Skeletal Muscle from Exhaustive Exercise-Induced Inflammation and Oxidative Stress Through the Nrf2/HO-1 Signaling Pathway","year":2025,"doi":"10.3390/antiox14020210","url":"https://doi.org/10.3390/antiox14020210","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_13","type":"source","study":"Sulforaphane alleviates hepatocyte pyroptosis via activating Nrf2-HO-1 signaling during septic acute liver injury","year":2025,"doi":"10.3389/fphar.2025.1690067","url":"https://doi.org/10.3389/fphar.2025.1690067","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_14","type":"source","study":"Effect of Glucoraphanin on the Abundance of Nrf2 Regulated Genes Within Circulating Small Extracellular Vesicles: A Pilot Dietary Intervention","year":2026,"doi":"10.1002/mnfr.70397","url":"https://doi.org/10.1002/mnfr.70397","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_15","type":"source","study":"Sulforaphane improves the bronchoprotective response in asthmatics through Nrf2-mediated gene pathways","year":2015,"doi":"10.1186/s12931-015-0253-z","url":"https://doi.org/10.1186/s12931-015-0253-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_16","type":"source","study":"Sulforaphane-Enriched Broccoli Sprouts Pretreated by Pulsed Electric Fields Reduces Neuroinflammation and Ameliorates Scopolamine-Induced Amnesia in Mouse Brain through Its Antioxidant Ability via Nrf2-HO-1 Activation","year":2019,"doi":"10.1155/2019/3549274","url":"https://doi.org/10.1155/2019/3549274","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_17","type":"source","study":"Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway","year":2018,"doi":"10.1016/j.redox.2017.12.016","url":"https://doi.org/10.1016/j.redox.2017.12.016","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_18","type":"source","study":"A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation","year":2016,"doi":"10.1186/s12931-016-0406-8","url":"https://doi.org/10.1186/s12931-016-0406-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_19","type":"source","study":"Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease","year":2016,"doi":"10.1371/journal.pone.0152895","url":"https://doi.org/10.1371/journal.pone.0152895","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_20","type":"source","study":"Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial","year":2016,"doi":"10.1371/journal.pone.0163716","url":"https://doi.org/10.1371/journal.pone.0163716","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_21","type":"source","study":"Sulforaphane is a Nrf2-independent inhibitor of mitochondrial fission","year":2016,"doi":"10.1016/j.redox.2016.11.007","url":"https://doi.org/10.1016/j.redox.2016.11.007","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_22","type":"source","study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_23","type":"source","study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_24","type":"source","study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_25","type":"source","study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"}],"edges":[{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_1","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_2","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_3","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_4","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_5","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_6","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_7","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_8","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_9","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_10","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_11","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_12","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_13","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_14","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_15","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_16","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_17","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_18","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_19","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_20","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_21","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_22","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_23","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_24","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_25","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_26","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_27","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_28","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_29","type":"contains_claim"},{"from":"c67a74c0-4be2-4dfe-9638-ee889fd68d14","to":"claim_30","type":"contains_claim"}],"screening":{"identified":21,"screened":21,"excluded":0,"included":21,"included_or_retained":21,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"21 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}